Cholesterol metabolism shapes immune low-response states in LUAD: a multi-omics cholesterol metabolism signature predicts immunotherapy benefit and identifies DHCR7 as a therapeutic target
Our study demonstrates that the CMS can effectively predict prognosis and immunotherapy response in LUAD. DHCR7, as a key gene in CMS, is closely related to immune suppression and poor prognosis. Inhibition of DHCR7 can improve the tumor immune microenvironment and enhance the efficacy of immunotherapy, suggesting that DHCR7 is a potential new target for LUAD immunotherapy.
Authors
- Jianan Zheng (ORCID: https://orcid.org/0009-0003-8268-0002)
- Guangyao Zhou (ORCID: https://orcid.org/0000-0002-8966-4617)
- Mingjun Du (ORCID: https://orcid.org/0000-0001-6151-4548)
- Yu Zhuang (ORCID: https://orcid.org/0000-0002-9640-9366)
- Wei Ye (ORCID: https://orcid.org/0009-0003-7331-8650)
- Chenjun Huang
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Nanjing Brain Hospital (CN)
- Nanjing Chest Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1696360
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94